Once-Weekly Islatravir and Lenacapavir Demonstrate Noninferiority to Daily B/F/TAF for HIV Suppression
Trial shows weekly islatravir and lenacapavir maintain HIV suppression
A Phase 3 trial confirms that once-weekly islatravir-lenacapavir maintains viral suppression comparable to daily B/F/TAF.
A new once-weekly pill combination showed similar success to daily treatment in keeping HIV levels suppressed for adults with the virus.
Islatravir 60 mg oral qm showed 64.3% adverse event rate compared to 77.1% in comparator
Trial Shows Islatravir Shows Tolerable Safety Profile for HIV Prevention
This Phase 3 randomized trial evaluated islatravir 60 mg oral qm in 494 cisgender men and transgender women at increased risk of HIV-1 expos…
A Phase 3 trial of islatravir for HIV prevention showed the medication was generally well tolerated with fewer reported side effects than th…
Evaluation of Once-Weekly Islatravir and Lenacapavir for Chronic HIV-1 Management
Trial shows once-weekly pill may match daily HIV treatment
A Phase 3 trial demonstrates that a once-weekly islatravir-lenacapavir regimen maintains viral suppression comparable to daily standard-of-c…
A new once-weekly pill could offer a simpler way to manage HIV, showing similar success to daily pills in a recent clinical trial.
Doravirine and islatravir combination shows reduced virological failure risk in adults with HIV-1
Trial shows doravirine and islatravir reduce HIV-1 treatment failure
This meta-analysis evaluated the efficacy of a doravirine and islatravir regimen compared to standard triple option therapy for patients liv…
A new two-drug combination for HIV-1 shows a significantly lower risk of treatment failure compared to standard triple therapy.
Islatravir and lenacapavir fixed-dose combination shows similar bioavailability to single agents in healthy volunteers
New HIV pill works with or without food in early safety tests
This open-label phase 1 study enrolled 93 people without HIV to assess the oral relative bioavailability and safety of a fixed-dose combinat…
A new HIV pill containing islatravir and lenacapavir showed similar drug levels whether taken with food or on an empty stomach, supporting f…
Phase 3 trial compares switch to doravirine/islatravir versus continuing bictegravir/FTC/TAF in HIV-1
Phase 3 trial compares two HIV drug regimens for people already virologically suppressed
A phase 3 randomized controlled trial enrolled 643 virologically suppressed adults with HIV-1 to compare switching to doravirine/islatravir …
People with HIV already on effective treatment can safely switch to a new two-drug pill without losing virus control, according to a complet…